Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TOP1
REST API REST API
Homo sapiens
TOP1 is differentially expressed in 323 experiments: 131 organism parts: liver, lung, ... (129 more);, 219 disease states: normal, control, ... (217 more);, 93 cell types 384 cell lines 50 compound treatments and 73 other conditions.
Orthologs TOP1 (Saccharomyces cerevisiae)   F1NPT1_CHICK (Gallus gallus)   top1l (Danio rerio)   ENSCING00000016260 (Ciona intestinalis)   F1MN93_BOVIN (Bos taurus)   F1M1S6_RAT (Rattus norvegicus)   Top1 (Mus musculus)   Top1 (Rattus norvegicus)   top1 (Danio rerio)   F6PHJ8_CIOIN (Ciona intestinalis)   Top1 (Drosophila melanogaster)   ENSXETG00000013237 (Xenopus laevis)   Q9XT65_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term phosphorylation, DNA binding, protein binding, cytoplasm, embryonic cleavage, nuclear chromosome, programmed cell death, ATP binding, nucleus, chromatin DNA binding, nucleotide binding, response to drug, DNA topoisomerase (ATP-hydrolyzing) activity, chromatin binding, chromosome, nucleoplasm, DNA topological change, DNA topoisomerase type I activity, DNA replication, nucleolus, perikaryon, interspecies interaction between organisms
InterPro Term TopoI_cat_euk, TopoI_C_euk, TopoI_C, TopoI_DNA-bd_euk
UniProt Accession P11387, Q9BVT2
Search EB-eye ENSG00000198900
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (43 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
U87
2
E-GEOD-20089, E-MEXP-903
BT-474
2
E-GEOD-3529, E-GEOD-5823
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
PC3
2
E-GEOD-5258, E-MEXP-2034
378 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-360, ... (45 experiments)

Factor Value U/D Experiments
stromal cell
4
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998, E-GEOD-10797
monocyte
3
E-GEOD-8286, E-MEXP-583, E-GEOD-22373
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-TABM-145, E-AFMX-5
CD34+
2
E-TABM-145, E-AFMX-5
87 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (75 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-MEXP-2034, E-MTAB-62, E-MTAB-37, E-GEOD-96, E-MEXP-1327 ... (5 experiments)
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
hepatocellular adenoma
2
E-TABM-36, E-MTAB-62
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
dermatomyositis
2
E-MTAB-62, E-GEOD-1551
213 more value(s).


Compound treatment

studied in E-GEOD-5542, E-TABM-782, E-GEOD-697, E-GEOD-3720, E-GEOD-5824, ... (32 experiments)

Factor Value U/D Experiments
none
3
7
E-GEOD-1740, E-MEXP-1601, E-GEOD-412, E-GEOD-2803, E-GEOD-5824, ... (10 experiments)
actinomycin D
1
E-GEOD-6400
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
M-CSF
1
E-GEOD-5099
interleukin-20 (Homo sapiens)
1
E-GEOD-7216
phenol
1
E-GEOD-6907
44 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-TABM-36, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, ... (9 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-MEXP-1437, E-GEOD-17476, E-GEOD-21750, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MEXP-2069, E-GEOD-1926, E-GEOD-16363, E-GEOD-430, ... (36 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-512, ... (6 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-22229, E-GEOD-1309, E-GEOD-22309, E-GEOD-1657, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-19330

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19136 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.356 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM